Typesetting丨Shuicheng WenRecently,BioAge LabsThe company revealed its listing plan, planning to go public through an IPO andPrivate placement raised approximately$180 millionFunding to advance clinical trials of its candidate weight-loss drug. The company has cumulatively raised nearly 300 million US dollars in previous financing rounds, of which the amount for the Series D round completed in February this year was 170 million US dollars.BioAge Labs PlanSelling 10.5 million shares at a price of $17-19 per share, excluding the IPO, BioAge LabsSofinnova Investments, one of the existing shareholders, is expected to purchase $10.6 million worth of the company's stock in a private placement.BioAge Labs is an anti-aging research company,Dedicated to developing treatments for disease and extending healthy lifespan by mapping the human aging atlas.Currently, BioAge Labs' preferred candidate drug isAzelaprag, a small molecule, oral Apelin receptor agonist, is currently under development in collaboration with Eli Lilly's weight loss drugTirzepatide(GIP/GLP-1 Receptor Dual Agonist)Phase 2 Clinical Trial of Combination Therapy for Obesity, Prior Preclinical and Phase 1 Clinical Studies Show,Azelaprag Improves Metabolic and Muscle Function, Significantly Enhances Weight Loss, and Optimizes Body Composition and Muscle Function in Patients Treated with GLP-1 Class Drugs.In addition, a clinical trial of Novo Nordisk's weight-loss drug will be conducted in the first half of next year.Semaglutide(GLP-1 Receptor Agonist)Phase 2 Clinical Trial for Combination Therapy in Obesity.In June 2022, the FDA approvedNovo NordiskDeveloped by the companySemaglutide（Semaglutide）As a weight-loss drug on the market, the drug quickly gained popularity worldwide in the same year, achieving sales exceeding 10 billion US dollars. In 2023, sales surpassed 20 billion US dollars. This is a peptide-based GLP-1 receptor.（GLP-1R）Agonist, in previous clinical trials, semaglutide achieved a 15% weight loss effect in obese patients.(Once weekly injection, 2.4mg each time, for 68 weeks)。And the GIP/GLP-1 receptor dual agonist developed by Eli LillyTirzepatide（Tirzepatide）This has achieved the strongest drug weight loss effect to date. On October 15, 2023, Eli Lilly and Company, in collaboration with a research team from the University of Pennsylvania and other institutions, published in a top international medical journal.Nature MedicinePublish papers.This project is namedResults from the Phase 3 clinical trial of SURMOUNT-3 show, over a 12-week periodStrengthen Lifestyle Interventions(Including low-calorie diet, exercise, and frequent counseling)After useTirzepatide（Tizepatide）Treatment for 72 weeks, totaling 84 weeks.Participants who are obese or overweight but do not have diabetesThe average weight loss was26.6%(29.2 kg). This data刷新了directly using tirzepatide（Tizepatide）Weight Loss Effect Record at 72 Weeks of TreatmentHowever, likeSemaglutide（Semaglutide）AndTirzepatide（Tirzepatide）This is mainly based onGLP-1The weight loss effect of these drugs is significant, but their core principle of weight loss is to reduce the user's appetite and calorie intake. Therefore,These drugs bring about weight loss while alsoWill also lead to a decline in muscle mass.。On October 26, 2023, BioAge Labs announced that it had received support from Eli Lilly and Company to advance its muscle regeneration therapy.AzelapragLilly's Tirzepatide（Tirzepatide）Combined, to conduct a healthier weight-loss clinical trial. It is reported that in this collaboration, BioAge Labs will retain the exclusive rights to develop and commercialize Azelaprag for all indications globally. BioAge Labs will...（BGE-105）Lilly's Tirzepatide（Tirzepatide）In collaboration, a Phase 2 clinical trial will be conducted with the primary goal of weight loss, secondary goals include other potential benefits. Additionally, BioAge Labs will collect information on aging-related biomarkers from participants.
Azelapra is an agonist of the Apelin receptor, mimicking the activity of Apelin. Apelin is an "exercise factor" peptide released after exercise. Apelin acts on skeletal muscle, the heart, and the central nervous system to regulate metabolism and promote muscle regeneration. Research from BioAge Labs shows,Throughout life, overall Apelin levels gradually decline, while individuals with higher Apelin levels exhibit stronger physical function and longer lifespans.BioAge Labs once combined Azelaprag with in preclinical mouse modelsTirzepatide（Tirzepatide）When used in combination, it shows advantages compared to using alone.Tirzepatide（Tirzepatide）Better weight loss results. BioAge LabsAzelaprag andTirzepatide（Tirzepatide）The combination has benefits in terms of energy metabolism, increased insulin sensitivity, and reduced fat mass.In December 2022, BioAgeLabsThe published results of the Phase 1b clinical trial of Azelaprag showed,Azelaprag Can Prevent Muscle Atrophy and Maintain Muscle Protein Synthesis in Healthy Elderly Adults Aged 65 or Older.CEO of BioAgeKristen FortneyDr. stated,The oral administration of Azelaprag makes it an exciting combination partner for the next generation of oral weight-loss drugs currently under development. Additionally, Azelaprag offers extra benefits that may helpPromote Healthier Weight LossTreating obesity has the potential to prevent or delay a variety of age-related diseases and significantly increase the lifespan of a large portion of the population.BioAge currently has three research directions, respectively for the treatment ofMetabolism and Muscle Aging、ImmunosenescenceAndBrain Aging。https://www.nature.com/articles/s41591-023-02597-whttps://www.businesswire.com/news/home/20231026896677/en/https://www.businesswire.com/news/home/20240213546755/en/
SettingsStar Marker`, Not Missing Any Exciting Tweets`Welcome to forward to Moments and WeChat groupsTo promote the dissemination and exchange of cutting-edge research, we have established severalProfessional Exchange Group, Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include a note when adding WeChat:School/Professional/Name, if it isPI/Professor, please also indicate.
PointIn View, Convey Your Taste
